AC Immune’s (ACIU) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of AC Immune (NASDAQ:ACIU) in a research report report published on Friday,Benzinga reports. HC Wainwright currently has a $16.00 price target on the stock.

Separately, StockNews.com lowered shares of AC Immune from a “buy” rating to a “hold” rating in a research report on Tuesday, October 1st.

AC Immune Trading Down 1.7 %

NASDAQ ACIU opened at $3.14 on Friday. AC Immune has a 12 month low of $2.25 and a 12 month high of $5.14. The stock has a market cap of $310.18 million, a price-to-earnings ratio of -7.07 and a beta of 1.28. The company’s 50 day moving average is $3.28 and its two-hundred day moving average is $3.49.

Hedge Funds Weigh In On AC Immune

Hedge funds and other institutional investors have recently bought and sold shares of the business. Lazard Asset Management LLC acquired a new stake in AC Immune in the 1st quarter valued at $30,000. BNP Paribas Financial Markets grew its stake in AC Immune by 315.6% in the 1st quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock valued at $33,000 after acquiring an additional 8,423 shares during the period. Silverberg Bernstein Capital Management LLC acquired a new stake in AC Immune in the 2nd quarter valued at $40,000. Vanguard Capital Wealth Advisors acquired a new stake in AC Immune in the 2nd quarter valued at $56,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in AC Immune by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock valued at $72,000 after acquiring an additional 7,400 shares during the period. Institutional investors and hedge funds own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.